Blog

While the January 2025 FDA guidance suggests PK approaches as starting points, our extensive experience implementing biomarker assays reveals why each validation parameter demands careful scientific consideration. Let’s explore how these distinct approaches come together to form a comprehensive, scientifically sound validation framework. Understanding the Fundamental Distinction The key to understanding biomarker validation lies in…

The January 2025 FDA Biomarker Assay Validation guidance suggests starting with PK validation approaches. However, our extensive experience implementing biomarker assays reveals why sample stability assessment demands a fundamentally different scientific approach. Understanding Traditional Drug Assay Validation In drug concentration assays, stability evaluation follows a straightforward path: analysts prepare spiked control samples and demonstrate accurate…

The January 2025 FDA Biomarker Assay Validation guidance suggests using PK validation approaches as a starting point. However, when it comes to dilutional linearity and parallelism, our extensive implementation experience reveals a fundamental scientific distinction that demands careful consideration. Understanding Traditional Drug Assay Validation In drug concentration assays, dilutional linearity serves as a cornerstone validation…